Diabetes mellitus is becoming a global epidemic burden. Its chronic cardiovascular complications – myocardial infarction and stroke, are the main cause of death in diabetic patients. It was found that LDL cholesterol concentration is related to the increased coronary disease risk that could be successfully reduced by cholesterol-lowering therapy. Furthermore, preliminary evidence suggests that ameliorating dyslipidemia may be renoprotective in diabetic patients with proteinuria.

Ezetemibe is the first selective inhibitor of cholesterol absorption and it has demonstrated high efficacy in lowing cholesterol concentration and excellent safety profile. Preliminary data suggest that ezetimibe, combined to a drug that blocks the cholesterol synthesis (statins), could be even more effective in decreasing cholesterol concentration. The aim of this study is to evaluate whether ezetimibe-simvastatine combined therapy is superior than simvastatin mono-therapy in ameliorating the lipid profile and albuminuria in type 2 diabetic patients.

Condition	Intervention
Type 2 Diabetes	Drug: Statins, Ezetimibe

Further Study Details: 

Primary Outcomes: LDL-cholesterol, at 16 weeks of treatment.LDL-cholesterol is measured at -4, 0, 8, 12 and 16 weeks
Secondary Outcomes: Total cholesterol, apolipoprotein A1 and B, lipoprotein and triglycerides, at -4, 0, 8, 12 and 16 weeks; Explorative; Urinary albumin excretion, at -4,0,8 and 16 weeks
Expected Total Enrollment:  108

INTRODUCTION Diabetes mellitus contributes substantially to the global burden of disease, with an estimated 150 million people affected worldwide and its prevalence is expected to double by 2025. Myocardial infarction and stroke are common causes of major morbidity in people with diabetes, most of whose deaths are attributed to cardiovascular causes. Recent findings provide definitive evidences that cholesterol-lowering therapy can produce substantial reductions in the risk of heart attacks, stroke and revascularizations in diabetic patients even if they do not have high blood cholesterol concentrations.

Also preliminary evidence is available that ameliorating dyslipidemia may be renoprotective in diabetic patients with proteinuria.

Ezetimibe is the first member of a class of highly selective cholesterol absorption inhibitors that effectively and potently prevents the absorption of cholesterol by inhibiting the passage of biliary and dietary cholesterol across the wall of small intestine, without affecting absorption of other fat-soluble nutrients.

Many pre-clinical models have demonstrated the lipid-lowering and anti-atherosclerotic properties of ezetimibe as a single agent, and showed its synergistic effect in combination with HMGCoA reductase inhibitors (statins).

Phase I/II studies on patients with hypercholesterolemia have explored the safety and efficacy of ezetimibe mono-therapy and co-administration with simvastatin.In these studies, combined therapy was safety and invariably more effective than single therapy in ameliorating the lipid profile.

Ezetimibe had an excellent safety profile in standard toxicity studies in pre-clinical models. Clinical studies in patients with primary hyperlipidemia have also indicated that monotherapy with ezetimibe and coadministration with statin was both well tolerated. Whether ezetimibe-simvastatin combined therapy more effectively than simvastatin mono-therapy ameliorates the lipid profile and albuminuria in people with diabetes is worth investigating. Evidence of a superior efficacy of eztimibe-simvastatin would provide the rationale for a prospective trial aimed to explore the possibility of a superior cardioprotective and renoprotective effect of the combined therapy.

AIM

Primary:

To compare the effect of ezetimibe-simvastatin combination (10-40mg/day) and simvastatin (40mg/day) alone on LDL-cholesterol concentrations in type 2 diabetic patients with basal total cholesterol>135mg/dl and/or concomitant lipid lowering therapy with HMGCoA reductase inhibitors.

Secondary:

• To compare the effect of the above treatments on total cholesterol, apolipoprotein A1 and B, lipoprotein (a) and triglycerides concentrations.
• To evaluate the safety profile of these two treatments.

Explorative:

To explore the hypothesis that ameliorating dyslipidemia therapy may also result in a reduction of urinary albumin excretion rate.

DESIGN This will be a randomized, prospective, double-blind, parallel group study. Following a 4-week wash-out period from previous lipid-lowering therapy (if any) with HMGCoA reductase inhibitors or any other kinds of lipid-lowering drugs, patients will enter a two-month run-in phase with simvastatin 40mg per day. At completion of the run-in period, patients will be randomly allocated into two double-blind treatment arms, ezetimibe 10mg + simvastatin 40mg per day or placebo + simvastatin 40mg per day for a two-month treatment period.

Ages Eligible for Study:  18 Years   -   70 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus with stable antidiabetic treatment since at least three months.
• Total cholesterol concentrations >135mg/dl and /or concomitant lipid lowering therapy with HMGCoA inhibitors
• Serum creatinine ≤1.5mg/dl
• Urinary albumin excretion rate <200μg/min
• Written informed consent

Exclusion Criteria:

• History of myocardial infarction, stroke or hospital admission for angina within the previous 6 months;
• History of percutaneous transluminal coronary angioplasty or coronary artery bypass grafting;
• Clinically manifest heart failure (grade III or above according to New York Heart Association criteria);
• Poor glyceamic control (HbA1C >11%);
• Primary hyperlipidemia;
• Uncontrolled thyroid diseases;
• Infectious disease within 4 weeks of starting;
• Acute liver disease or hepatic dysfunction;
• Inflammatory muscle disease or evidence of muscle problems;
• Concurrent treatment with systemic steroids, androgens, cyclosporin and other immunosuppressive drugs, fibrates, high-dose niacin or cholestyramine;
• Pregnancy or lactating;
• Women of childbearing potential without following a scientifically accepted form of contraception;
• Life-threatening conditions or terminal concomitant diseases other than diabetes;
• Specific contraindications or history of hypersensitivity to the study drugs or other statins;
• Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequence of the trial;
• Evidence of an uncooperative attitude;
• Any evidence that patient will not be able to complete the trial follow-up.

Please refer to this study by ClinicalTrials.gov identifier  NCT00157482

Piero Ruggenenti, MD      003903545351  Ext. 405    ruggenenti@marionegri.it

Italy
      Hospital "Ospedali Riuniti di Bergamo" - Diabetologic Unit, Bergamo,  24128,  Italy; Recruiting
Italy, Bergamo
      Clinical Research Center for Rare Diseases, Ranica,  Bergamo,  24020,  Italy; Recruiting
      Hospital "Treviglio Caravaggio " - Diabetologic Unit, Treviglio,  Bergamo,  24047,  Italy; Recruiting
      ASl of Ponte San Pietro - Diabetologic Unit, Ponte San Pietro,  Bergamo,  24036,  Italy; Completed

Study chairs or principal investigators

Piero Ruggenenti, MD,  Principal Investigator,  Mario Negri Institute   

Study ID Numbers:  ESD
Last Updated:  September 10, 2005
Record first received:  September 8, 2005
ClinicalTrials.gov Identifier:  NCT00157482
Health Authority: Italy: Ministry of Health
ClinicalTrials.gov processed this record on 2005-09-13